Arnulf H. Hölscher

Arnulf H. Hölscher, MD, PhD is one of Europe's preeminent esophageal and gastric cancer surgeons, having performed over 2,000 esophagectomies and shaped modern standards for the surgical treatment of esophageal and gastroesophageal junction (GEJ) cancers. As founding director of the Contilia Centre for Oesophageal Diseases in Essen and a long-tenured professor at the University of Cologne, he built one of the highest-volume esophageal surgery programs in the world. His systematic work on en-bloc transthoracic esophagectomy with two-field lymphadenectomy established the oncologic principles underpinning curative-intent surgery for thoracic esophageal cancer in Western centers. Hölscher was among the leading surgical voices in the pivotal FLOT4-AIO phase III trial (Al-Batran et al., NEJM 2019) that demonstrated superiority of FLOT (docetaxel, oxaliplatin, leucovorin, 5-fluorouracil) over ECF/ECX perioperative chemotherapy for resectable gastric and GEJ adenocarcinoma—a trial that immediately changed global practice. He has championed multidisciplinary tumor boards and standardized pathological response grading to guide treatment decisions, and his research on lymph node dissection extent and its prognostic value has informed staging systems and guideline recommendations across Europe and Asia. Beyond surgery, he has published extensively on neoadjuvant strategies, prognosis after complete pathological response, and surgical quality metrics. His mentorship has produced a generation of senior European upper GI surgeons.